ArticleCureus2025
Insulin Resistance and Beta-Cell Function in the Context of Dyslipidemia in a Non-obese Indian Population With Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Insulin resistance (IR) and impaired beta-cell function (BCF) are central to type 2 diabetes (T2D) pathogenesis and influence lipid metabolism, causing dyslipidemia. While most dyslipidemia studies focus on obese individuals, data on non-obese populations are limited. This study explored the association between IR, BCF, and lipid profiles in non-obese Indian T2D patients. Methods A cross-sectional analysis was conducted on T2D patients (n=667) with a body mass index <25 kg/m², not on insulin or lipid-lowering medications, who participated in a one-year lifestyle intervention program at the Freedom from Diabetes Clinic, India. Clinical, anthropometric, and biochemical data were extracted from existing records. IR and BCF were assessed using homeostatic model assessment of IR (HOMA2-IR) and BCF (HOMA2-%B). Results The median age, HbA1c, and diabetes duration were 50 years, 7.6%, and nine years, respectively. Overall, 73.3% (n=489) were male, 4.2% (n=28) had IR (HOMA2-IR≥2.0), and 69.9% (n=466) had reduced BCF (HOMA2-%B<50). HOMA2-IR showed a positive correlation with triglycerides and non-high-density lipoprotein cholesterol (non-HDL-C) (P<0.001) and a negative correlation with HDL-C (P<0.001). HOMA2-%B was negatively associated with total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and HDL-C (P<0.05). Receiver operating characteristic (ROC) analysis demonstrated that triglycerides (area under the curve (AUC)=0.648, P=0.008), non-HDL-C (AUC=0.626, P=0.023), and HDL-C in men (AUC=0.706, P=0.003) had fair discriminatory ability for IR. HOMA2-%B failed to discriminate lipid abnormalities. Conclusion In non-obese Indian T2D patients, both IR and beta-cell dysfunction are associated with dyslipidemia. However, only IR demonstrated a fair discriminatory ability for identifying abnormal lipid profiles, whereas BCF did not. These findings underscore the need for further studies to understand the metabolic drivers of lipid abnormalities in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.